Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 897

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 5
Chunk 897
---
 No. 001-41351).

(4)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on April 12, 2023 (File No. 001-41351).

(5)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on July 13, 2023 (File No. 001-41351).

(6)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on November 20, 2023 (File No. 001-41351).

(7)Filed
as an exhibit to the Annual Report on Form 10-K filed with the SEC on March 17, 2023 (File No.001-41351).

(8)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on July 10, 2024 (File No. 001-41351).

(9)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on September 5, 2024 (File No. 001-41351).

(10)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on August 9, 2024 (File No. 001-41351).

(11)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on June 27, 2024 (File No. 001-41351).

(12)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on July 17, 2024 (File No. 001-41351).

(13)Filed
as an exhibit to the Annual Report on Form 10-K filed with the SEC on April 1, 2024 (File No. 001-41351).

37

SIGNATURES

Pursuant
to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

    April 1, 2025
    Denali Capital Acquisition Corp.

    By:
    /s/
    Lei Huang

    Name: 
    Lei Huang

    Title: 
    Chief Executive Officer

Pursuant
to the requirements of the Securities Exchange Act of 193